Anti-Cdc13 [6F11/2]

6F11/2 can be used for detecting Cdc13 and associated Cdk1 kinase activation.

Contributors

Inventor Institute
Jacqueline Hayles Cancer Research UK, London Research Institute: Lincoln's Inn Fields
SKU: 151061
Product description: 6F11/2 can be used for detecting Cdc13 and associated Cdk1 kinase activation.
Alternate name: Cell division control protein 13; YDL22C
Conjugation: Unconjugated
Isotype: IgG2a
Immunogen: Full length cdc13
Myeloma used: Sp2/0-Ag14
Cat. #: 151061
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Genetics
Application: WB ; IHC ; IP ; WB
Target: Cell-division cycle protein 13 (cdc13)
Reactivity: Schizosaccharomyces pombe
Clone: 6F11/2
Host: Mouse
Class: Monoclonal
Target background: Cdc13 is a fission yeast (S. pombe) B-type M-phase cyclin. Cdc13 binds to Cdk1 (cdc2), and the resulting Cdk1-Cdc13 complex controls the G2/M transition of the cell cycle.
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Rothe et al. 2017. J Cell Sci. 130(23):4028-4037. PMID: 29046339.

Koch et al. 2012. ACS Chem Biol. 7(4):723-31. PMID: 22264160.

Okuzaki et al. 2010. Cell Cycle. 9(18):3751-60. PMID: 20855961.

Decottignies et al. 2001. J Cell Sci. 114(Pt 14):2627-40. PMID: 11683390.

Images

View Gallery
Adapted from Koch et al. 2012. ACS Chem Biol; 7(4)

Related Tools for Antibodies

Cat. # Tool Name
151027 Anti-HSVICP8 [10A3] Key Info View Tool
151031 Anti-RuvA [RuvA 12C6] Key Info View Tool
151034 Anti-HSVUL42 [13D11] Key Info View Tool
151036 Anti-ICAM1 [15.2] Key Info View Tool
151035 Anti-CD8 [14] mAb Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.